Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
Authors:
Open Access
- 22 January 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (2) , 131-138
Abstract
Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations. Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions. The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.Keywords
Funding Information
- No funding
This publication has 24 references indexed in Scilit:
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER TrialDiabetes Care, 2020
- Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled TrialDiabetes Care, 2020
- The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysisAfrican Health Sciences, 2019
- American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with ObesityEndocrine Practice, 2016
- GLP‐1 analogue use in patients with sub‐optimally controlled type 1 diabetes or obesity improves weight and HbA1cPractical Diabetes, 2016
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine, 2015
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort DatabaseDiabetes Care, 2010
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled studyThe Lancet, 2009
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- The biology of incretin hormonesCell Metabolism, 2006